The CancerNetwork® and the journal ONCOLOGY® Tumor Board was assembled to bring together some of the brightest minds and leading voices in cancer care.
These multidisciplinary experts partner with CancerNetwork® and the journal ONCOLOGY®to share their knowledge through articles, video programs, podcasts, 1:1 interviews, panel discussions, and interactive events.
Get to know more about each member and explore some of their work with CancerNetwork® and the journal ONCOLOGY®.
Tanios S. Bekaii-Saab, MD
Gastrointestinal Cancer Chair
Leader, Gastrointestinal Program
Medical Director, Cancer Clinical Research Office
Vice Chair and Section Chief for Medical Oncology, Department of Internal Medicine
Tanios S. Bekaii-Saab, MD, is a professor of Medicine at the Mayo Clinic College of Medicine and Science, leader of the Gastrointestinal Cancer Program at the Mayo Clinic Cancer Center, medical director of the Cancer Clinical Research Office, vice chair and section chief for Medical Oncology for the Division of Hematology/Oncology in the Department of Internal Medicine at the Mayo Clinic in Phoenix, Arizona. Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana and has practiced for over 20 years. His research interests in gastrointestinal cancers are focused on the incorporation of agents that target the multiple facets of cancer, including genetic and epigenetic drives as well as the feeding microenvironment and the immune milieu. The primary goal of his work is helping patients to identify those techniques best suited for their individual situation.
Hossein Borghaei, DO, MS
Thoracic Malignancies Chair
Chief, Division of Thoracic Medical Oncology
Professor, Department of Hematology/Oncology
Co-Director, Immune Monitoring Facility
Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Fox Chase Cancer Center
Hossein Borghaei, MS, DO, is the chief of Thoracic Medical Oncology, professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, and the Gloria and Edmund M. Dunn Chair in Thoracic malignancies. Borghaei earned his degree at Philadelphia College of Osteopathic Medicine and completed a residency at Graduate Hospital in Philadelphia. Since completing his fellowship training at Fox Chase, he has been involved in a number of clinical trials aimed at developing new, antibody-based therapies and immunotherapies for patients with lung cancer.
Mehmet Sitki Copur, MD, FACP
Member, Community Oncology Editorial Board
Professor of Hematology/Oncology, Department of Internal Medicine
University of Nebraska Medical Center
Faculty of the Department of Medical Oncology
Morrison Cancer Center
Mehmet S. Copur, MD, FACP, is a nationally known medical oncologist in Grand Island, Nebraska and is affiliated with multiple hospitals in the area, including Veterans Affairs Black Hills Health Care System-Forte Mead and CHI Health St. Francis. He received his medical degree from Hacettepe University Faculty of Medicine in Turkey and has been in practice for more than 35 years. Copur is board-certified in Internal Medicine and Medical Oncology and serves on numerous committees.
Robert A. Figlin, MD
Genitourinary Cancer Chair
Deputy Director, Cedars-Sinai Cancer
Steven Spielberg Family Chair in Hematology-Oncology
Professor, Biomedical Sciences
Cedars-Sinai Medical Center
Los Angeles, CA
Robert A. Figlin, MD, is a professor of medicine and biomedical sciences, director of the Division of Hematology/Oncology, deputy director of the Samuel Oschin Comprehensive Cancer Institute, and deputy director of Integrated Oncology at Cedars-Sinai Medical Center in Los Angeles, California. Figlin received his medical degree from the Medical College of Pennsylvania. He completed his residency and chief residency in internal medicine at Cedars-Sinai Medical Center and a fellowship in hematology/oncology at the David Geffen School of Medicine at the University of California, Los Angeles. His major oncologic focus is in thoracic and genitourinary tumors. A nationally recognized leader in genitourinary and thoracic oncology, Figlin’s research focuses on renal cell carcinoma and thoracic malignancies.
Howard S. Hochster, MD
Co-Editor in Chief
Distinguished Professor of Medicine
Associate Director for Clinical Research and Director of GI Oncology
Rutgers Cancer Institute
Director of Oncology Research, RWJBarnabas Health
New Brunswick, NJ
Howard S. Hochester, MD, joined Rutgers Cancer Institute of New Jersey as the Associate director for Clinical Research and director of Gastrointestinal Oncology. Hochster is certified in Internal Medicine by the American Board of Internal Medicine, and by the Hematology and Oncology Boards. Hochester graduated from the Yale School of Medicine and completed an internship, residency, and fellowship in Hematology-Oncology at Bellevue Hospital and NYU Medical Center. His clinical expertise and research interests are dedicated to early drug development and clinical pharmacology focused on tumors of the gastrointestinal tract.
Sara A. Hurvitz, MD
Breast Cancer Chair
David Geffen School of Medicine
Jonsson Comprehensive Cancer Center Clinical Research Unit
Santa Monica-UCLA Outpatient Oncology Practices
Director of the Breast Cancer Clinical Trials
University of California Los Angeles
Los Angeles, CA
Hurvitz started her pursuit of medicine in 1990 when she enrolled at the University of California, Irvine, and went on to earn dual degrees in biology and psychology. Hurvitz is a medical oncologist who practices in the Santa Monica Parkside location, which houses the University of California, Los Angeles Health integrative breast cancer practice and high-risk breast cancer clinic. Hurvitz specializes in the treatment of women with breast cancer. She is involved in constructing and implementing several national clinical trials testing new therapies while studying gene expression patterns in a variety of breast cancer populations with the goal of developing novel therapies.
Ola Landgren, MD, PhD
Multiple Myeloma Cancer Chair
Chief, Myeloma Program
Leader, Experimental Therapeutics Program
Sylvester Comprehensive Cancer Center
Professor of Medicine
University of Miami
Hematologic oncologist, Ola Landgren, MD, PhD, was recently appointed the inaugural leader of a new research program, Experimental Therapeutics, at Sylvester Comprehensive Cancer Center at the University of Miami Health System and the Miller School of Medicine. Landgren completed his medical degree and doctorate at Karolinska Institute in Stockholm, Sweden. He is board certified in hematology and internal medicine. As part of his ongoing research program, Landgren is studying molecular mechanisms underlying the trajectory from precursor to full-blown multiple myeloma with the goal to develop treatment strategies aiming to delay, prevent, and ultimately define a cure for multiple myeloma.
Judd W. Moul, MD
Member, Genitourinary Cancers Editorial Board
James H. Semans, MD, Distinguished Professor of Urologic Surgery
Professor of Surgery
Professor in Anesthesiology
Duke University School of Medicine
Judd W. Moul, MD, is a retired colonel and a noted researcher and clinician in prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H. Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology. Moul has served as the Editor for Prostate Cancer and Prostatic Disease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World.
Eric J. Sherman, MD
Head and Neck Cancer Chair
Head and Neck Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Eric J. Sherman, MD, is a medical oncologist in New York, New York and is affiliated with Memorial Sloan Kettering Cancer Center. Sherman received his medical degree from Columbia University College of Physicians & Surgeons and has been in practice for more than 20 years while dedicated to improving the lives of patients with head and neck cancer. Sherman’s primary clinical and research focus is on thyroid cancers and squamous cell carcinomas of the head and neck. He also has a vast interest in diagnosing and treating the less common cancers of the head and neck, such as sinonasal undifferentiated carcinomas and salivary gland tumors.
Julie M. Vose, MD, MBA
Co-Editor in Chief
Professor, Internal Medicine
Chief of Hematology & Oncology, Department of Internal Medicine
University of Nebraska Medical Center College of Medicine
Associate Director of Clinical Research
Fred and Pamela Buffet Cancer Center
Julie M. Vose, MD, MBA, is the Neumann M. and Mildred E. Harris professor and the chief of the Division of Oncology/Hematology in the Department of Internal Medicine at University of Nebraska Medical Center (UNMC). Vose graduated from Medical School at UNMC, completed her internal medicine residency as well as a Chief Resident year, followed by a Hematology/Oncology Fellowship at UNMC, and has been on faculty since 1990. Vose is an internationally known leading expert in the treatment of patients with Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), and chronic lymphocytic leukemia. She is actively involved in many novel clinical trials for lymphoma including targeted agents, monoclonal antibodies, and cellular therapy. Vose has been recognized for her NHL research on a national and international level through research awards and invited lectureships worldwide.